BR112017017685A2 - formulações farmacêuticas de inibidor de c1 esterase - Google Patents
formulações farmacêuticas de inibidor de c1 esteraseInfo
- Publication number
- BR112017017685A2 BR112017017685A2 BR112017017685A BR112017017685A BR112017017685A2 BR 112017017685 A2 BR112017017685 A2 BR 112017017685A2 BR 112017017685 A BR112017017685 A BR 112017017685A BR 112017017685 A BR112017017685 A BR 112017017685A BR 112017017685 A2 BR112017017685 A2 BR 112017017685A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulations
- esterase inhibitor
- inhibitor pharmaceutical
- inh
- prevention
- Prior art date
Links
- 229940009550 c1 esterase inhibitor Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract 2
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 229960000948 quinine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15156010 | 2015-02-20 | ||
| PCT/EP2016/053559 WO2016131958A1 (en) | 2015-02-20 | 2016-02-19 | Pharmaceutical formulations of c1 esterase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017017685A2 true BR112017017685A2 (pt) | 2018-04-10 |
Family
ID=52573617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017685A BR112017017685A2 (pt) | 2015-02-20 | 2016-02-19 | formulações farmacêuticas de inibidor de c1 esterase |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180036394A1 (enExample) |
| EP (1) | EP3258911A1 (enExample) |
| JP (1) | JP6516855B2 (enExample) |
| KR (1) | KR20170118856A (enExample) |
| CN (1) | CN107257683A (enExample) |
| AU (1) | AU2016221627A1 (enExample) |
| BR (1) | BR112017017685A2 (enExample) |
| CA (1) | CA2977090A1 (enExample) |
| IL (1) | IL253824A0 (enExample) |
| MX (1) | MX2017010323A (enExample) |
| RU (1) | RU2017132449A (enExample) |
| SG (1) | SG11201706019XA (enExample) |
| WO (1) | WO2016131958A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190175683A1 (en) | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| BR112019023737A2 (pt) * | 2017-05-16 | 2020-05-26 | Octapharma Ag | Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea |
| CN120381522B (zh) * | 2025-04-02 | 2026-01-23 | 南方医科大学南方医院 | 一种治疗肝硬化门脉高压的化合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012311483B2 (en) * | 2011-09-24 | 2016-03-10 | Csl Behring Gmbh | Combination therapy using immunoglobulin and C1-inhibitor |
| ME03326B (me) * | 2013-03-15 | 2019-10-20 | Shire Viropharma Inc | C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze |
-
2016
- 2016-02-19 JP JP2017543934A patent/JP6516855B2/ja not_active Expired - Fee Related
- 2016-02-19 WO PCT/EP2016/053559 patent/WO2016131958A1/en not_active Ceased
- 2016-02-19 BR BR112017017685A patent/BR112017017685A2/pt not_active Application Discontinuation
- 2016-02-19 CN CN201680010988.7A patent/CN107257683A/zh active Pending
- 2016-02-19 US US15/551,256 patent/US20180036394A1/en not_active Abandoned
- 2016-02-19 RU RU2017132449A patent/RU2017132449A/ru not_active Application Discontinuation
- 2016-02-19 CA CA2977090A patent/CA2977090A1/en not_active Abandoned
- 2016-02-19 KR KR1020177026457A patent/KR20170118856A/ko not_active Withdrawn
- 2016-02-19 AU AU2016221627A patent/AU2016221627A1/en not_active Abandoned
- 2016-02-19 MX MX2017010323A patent/MX2017010323A/es unknown
- 2016-02-19 SG SG11201706019XA patent/SG11201706019XA/en unknown
- 2016-02-19 EP EP16705521.9A patent/EP3258911A1/en not_active Withdrawn
-
2017
- 2017-08-03 IL IL253824A patent/IL253824A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018509398A (ja) | 2018-04-05 |
| MX2017010323A (es) | 2017-12-07 |
| IL253824A0 (en) | 2017-09-28 |
| US20180036394A1 (en) | 2018-02-08 |
| AU2016221627A1 (en) | 2017-08-17 |
| SG11201706019XA (en) | 2017-09-28 |
| CN107257683A (zh) | 2017-10-17 |
| EP3258911A1 (en) | 2017-12-27 |
| RU2017132449A (ru) | 2019-03-21 |
| CA2977090A1 (en) | 2016-08-25 |
| KR20170118856A (ko) | 2017-10-25 |
| JP6516855B2 (ja) | 2019-05-22 |
| WO2016131958A1 (en) | 2016-08-25 |
| RU2017132449A3 (enExample) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230073A1 (ar) | بنزاميدات مستبدلة مع 3،1- ثيازول-2- يل | |
| AU2016278853A8 (en) | Petrolatum-based compositions comprising cationic biocides | |
| BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
| BR112018010018A2 (pt) | moduladores de ror-gama | |
| JOP20170107B1 (ar) | مشتقات سلفوناميد عطرية | |
| EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112015023207A8 (pt) | composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase. | |
| WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| EP4553065A3 (en) | Novel compounds for treating mitochondrial disease | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| MX381776B (es) | Formulacion acuosa que comprende paracetamol e ibuprofeno. | |
| CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA201991898A1 (ru) | Двойные ингибиторы magl и faah | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| UY36248A (es) | ?una dispersión a base de agua o aceite, formulaciones y método para prepararlas, y uso de las dispersiones o formulaciones?. | |
| CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| SA520420261B1 (ar) | تركيبات إرنوماب واستخداماتها | |
| TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
| EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
| CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| MX374705B (es) | Composiciones que comprenden anakinra. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |